Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the months of August and September 2004

Commission File Number 000-28966

Biacore International AB (publ)

C/o Biacore International SA
Puits-Godet 12
CH-2000 Neuchatel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.

Form 20-F  X
Form 40-F

Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act 
of 1934.

No   X

If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): Not applicable.


Uppsala, Sweden, September 20, 2004.

Biacore International AB (Biacore) announces that it has appointed Mr. Jerry
Williamson as the new President of Biacore Inc. Mr. Williamson will assume his
new role immediately and will play a vital role in positioning Biacore's U.S.
sales organization to maximize the potential of the Company's product offering
in the world's largest life science instrument market. Mr. Williamson takes over
from Mr. Thomas P Wida who is leaving the Company.

Mr. Williamson, who was until recently the President of Pyrosequencing Inc., has
over eighteen years experience working in the U.S. life science industry. At
Pyrosequencing, he was responsible for increasing the U.S. sales of the company
significantly while at the same time bringing costs down to more appropriate
levels. Mr. Williamson joins Biacore from Beacon BioPartners, a strategic and
business consultancy focused on the life science sector where he was the
Managing Partner. Prior to joining Pyrosequencing in 2000, Mr. Williamson worked
for a number of emerging biotechnology companies, as well as major industry
heavyweights such as Roche. His experience includes sales management, marketing,
business development and recruitment.

Mr. Erik Wallden, President and CEO of Biacore commenting on today's appointment
said "I am pleased to welcome Jerry on board. I am sure his vast experience of
the U.S. life science industry will allow him to bring a new commercial dynamic
to Biacore Inc's operations." It is clear from our review of Biacore's business
activities that we need to bring a new, much more aggressive commercial culture
to our U.S. activities. This will enable us to maximize the potential of our
full range of products for protein interaction analysis and deliver the sales
that I believe we are capable of achieving in the world's most important life
science instrument market.

"I would at this point like to express my thanks to Tom for all his work over
the last several years and wish him every success in his future career." Mr.
Wallden added.

The cost that Biacore incurs for the termination of Mr. Wida's contract will be
reported in the third quarter 2004 and is estimated at approximately SEK 3.2

Biacore is currently undertaking a strategic business review focused on a number
of areas of the Company's operations including its sales processes. Biacore
expects to announce the full results of this business review on or before its
3rd Quarter results which are due to be announced 21st October 2004.

About Biacore

Biacore is a global supplier of analytical systems that improve the productivity
of research and development in the life science, pharmaceutical and diagnostic
markets. The company's instruments generate unique data on protein interactions,
an area of increasing focus in these markets. These data give insights into
protein functionality, the role of proteins in normal and diseased states, and
the influence of potential drug candidates.

Use of Biacore products is well-documented in key areas such as antibody
characterization, proteomics, lead optimization and bio-therapeutic development
and production. Customers include leading life science research centers, all of
the leading global pharmaceutical companies, diagnostic companies and a large
number of companies in the emerging biotechnology sector. Biacore is
successfully expanding into the food analysis market, providing key
manufacturers with ready-to-use solutions for the determination of food quality
and safety.

All instruments utilize surface plasmon resonance (SPR) technology as the basis
for detection and monitoring of protein interactions. Biacore has its own direct
sales capability in the world's key markets, United States, Europe, Japan,
Australia and a distribution network in Asia-Pacific. The company was created in
1984. Based in Uppsala, Sweden, the Company is listed on Stockholmsborsen.

Further information on Biacore can be found on the web:


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: October 5, 2004
Biacore International AB (publ)
By: Lars-Olov Forslund
Name: Lars-Olov Forslund
Title: Chief Financial Officer